Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Change in Receivables (2016 - 2025)

Avanos Medical's Change in Receivables history spans 11 years, with the latest figure at -$300000.0 for Q4 2024.

  • For Q4 2024, Change in Receivables rose 96.67% year-over-year to -$300000.0; the TTM value through Dec 2024 reached $6.6 million, up 116.92%, while the annual FY2025 figure was -$30.9 million, 568.18% down from the prior year.
  • Change in Receivables for Q4 2024 was -$300000.0 at Avanos Medical, down from $7.7 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $18.7 million in Q4 2022 and bottomed at -$26.2 million in Q1 2023.
  • The 5-year median for Change in Receivables is -$600000.0 (2022), against an average of -$2.1 million.
  • The largest annual shift saw Change in Receivables skyrocketed 6133.33% in 2022 before it crashed 1133.33% in 2023.
  • A 5-year view of Change in Receivables shows it stood at -$11.5 million in 2020, then surged by 102.61% to $300000.0 in 2021, then surged by 6133.33% to $18.7 million in 2022, then crashed by 148.13% to -$9.0 million in 2023, then surged by 96.67% to -$300000.0 in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Change in Receivables are -$300000.0 (Q4 2024), $7.7 million (Q3 2024), and $7.4 million (Q2 2024).